Switch to
More onapp

Thyrocare Technologies Ltd

THYROCARE
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹3,249 cr, stock is ranked 647
Moderate RiskStock is 2.05x as volatile as Nifty
615.351.50 (+0.24%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹3,249 cr, stock is ranked 647
Moderate RiskStock is 2.05x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
18.49
PB RatioPB Ratio
6.19
Dividend YieldDiv. Yield
2.44%
Sector PESector PE
58.66
Sector PBSector PB
10.01
Sector Div YldSctr Div Yld
0.63%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Thyrocare Technologies Limited is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. It also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.

Investor PresentationView older 

Nov 11, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

2019202020212022413.52441.44507.05618.1185.1488.40113.15176.14
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 2.08%

See detailed holdings

Recent EventsAll events 

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 25, 2022

Thyrocare Technologies Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Thyrocare Technologies Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Related Party Transaction 
Announced OnNov 25, 2022

Thyrocare Technologies Limited has informed the Exchange about related party transaction for the period ended September 2022. | Download

Thyrocare Technologies Limited has informed the Exchange about related party transaction for the period ended September 2022. | Download

Cash Dividend 
Ex. DateMay 11, 2022

Interim • Div/Share: ₹ 15

See all events